This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

Dosing

XELJANZ 5 mg BID and 11 mg prolonged release QD are the only approved dosages for the treatment of RA. XELJANZ prolonged release 11 mg QD is pharmacokinetically equivalent to XELJANZ 5 mg BID.

Another treatment option for Rheumatoid Arthritis (RA) patients1

Always refer to the full Prescribing Information before prescribing XELJANZ.

Tablets shown not true to size.
​​​​​​​Note: the dose should not be exceeded

  • Can be given with or without food.
  • XELJANZ 5mg tablets may be crushed and taken with water.
  • XELJANZ 11 mg prolonged release tablets must be taken whole in order to ensure the entire dose is delivered correctly. They must not be crushed, split or chewed.
  • No dose adjustment required when used in combination with MTX.
  • XELJANZ treatment should be interrupted if a patient develops a serious infection until the infection is controlled.
  • Terminal half-life of approximately 3 hours for XELJANZ 5 mg tablets and approximately 6 hours for XELJANZ 11 mg prolonged release tablets.
  • XELJANZ is available in a 28-day treatment pack.
  • XELJANZ contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
​​​​​​​Packs and tablets shown not true to size.


​​​​​​​Contraindications and special populations1

Contraindications for use:

  • Hypersensitivity to the active substance or to any of the excipients*.
  • Active tuberculosis (TB), serious infections such as sepsis, or opportunistic infections.
  • Severe hepatic impairment.
  • Pregnancy and lactation.

Special populations:

Renal Impairment
  • XELJANZ dose should be reduced to 5 mg once daily in patients with severe renal impairment (creatinine clearance <30 mL/min).
  • Patients with severe renal impairment should remain on a reduced dose of 5 mg once daily even after haemodialysis.
Hepatic impairment
  •  XELJANZ dose should be reduced to 5 mg once daily in patients with moderate hepatic impairment (Child Pugh B).
  • XELJANZ should not be used in patients with severe hepatic impairment (Child Pugh C).
Elderly
  • No dose adjustment is required in patients aged ≥65 years based on age alone (see other special populations). There are limited data in patients aged 75 years and older.
  • The elderly population in general has an increased risk of infections; caution should be used when treating the elderly. In patients over 65 years of age XELJANZ should only be considered if no suitable alternative treatment is available.​​​​​​​
Other
  • XELJANZ should only be used in patients over 65 years of age, In patients who are current or past smokers, patients with other cardiovascular risk factors, and patients with other malignancy risk factors if no suitable treatment alternatives are available.​​​​​​​

Drug-drug interactions

  • XELJANZ dose should be reduced to 5 mg once daily in patients receiving potent inhibitors of CYP3A4 (e.g., ketoconazole).
  • XELJANZ dose should also be reduced to 5 mg once daily in patients receiving one or more concomitant medicines that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g. fluconazole).
  • Co-administration of XELJANZ with potent CYP inducers (e.g. rifampicin) may result in a loss of, or reduced, clinical response.
  • Co-administration of potent inducers of CYP3A4 with XELJANZ is not recommended.

Explore more

JAK Selectivity in RA

Watch Professor Ernest Choy's lecture on understanding the clinical significance of JAK selectivity in RA

Watch video


* XELJANZ contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

MTX - methotrexate; BID - twice daily; QD - once daily; TB - tuberculosis; RA - rheumatoid arthritis; PsA - psoriatic arthritis.

PP-XEL-GBR-3109. August 2021

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

Dosing in RA

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No